Background: The relationship between expression of FoxM1 and clinical parameters of patients with gastric cancer (GC) has yet to be fully established.
Methods: A systematic search was performed. Odds ratio (OR) and confidence interval (CI) were used to assess association between expression of FoxM1 and clinical parameters and the prognostic value of patients with GC.
Results: Eight studies involving 529 patients with GC were identified. Overall, the pooled results showed that expression of FoxM1 was associated with TNM stage (OR: 0.482, 95%CI: 0.275-0.845, P = 0.011), depth of invasion (OR: 0.617, 95%CI: 0.382-0.998, P = 0.049) and lymph node metastasis (OR: 2.084, 95%CI: 1.305-3.328, P = 0.002) in the patients with GC. Whereas, expression of FoxM1 was not associated with gender (OR: 1.143, 95%CI: 0.726-1.799, P = 0.564) and tumors' differentiation (OR: 0.991, 95%CI: 0.624-1.575, P = 0.971) of GC. Expression of FoxM1 was also associated with poor prognosis of overall survival (OS) in the patients with GC (one year OS: OR: 0.218, 95%CI: 0.103-0.459, P = 0.000; three years OS: OR: 0.178, 95%CI: 0.093-0.340, P = 0.000; five years OS: OR: 0.180, 95%CI: 0.095-0.341, P = 0.000).
Conclusion: Expression of FoxM1 is associated with TNM stage, depth of invasion, lymph node metastasis and poor prognosis of the patients with GC.
Keywords: Clinical parameters; FoxM1; Gastric cancer; Meta-analysis; Prognosis.
Copyright © 2017. Published by Elsevier Ltd.